BioMarin Pharmaceuticals BMRN Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.24B+9.9% | $3.22B+12.9% | $3.09B+12.4% | $3.06B+18.4% | $2.95B+19.4% | ||
| $760.88M+25.4% | $717.44M+23.6% | $577.87M-0.7% | $626.24M+20.1% | $606.61M+16.3% | ||
| $2.48B+5.9% | $2.5B+10.1% | $2.52B+15.9% | $2.44B+17.9% | $2.34B+20.2% | ||
| 76.5%-2.9pp | 77.7%-1.9pp | 81.3%+2.5pp | 79.6%-0.3pp | 79.4%+0.5pp | ||
| $942M+34.4% | $921.93M+23.4% | $903.03M+15.8% | $678.45M-13.7% | $700.93M-10.1% | ||
| $1.21B+21.8% | $1.15B+14.3% | $973.42M-2.8% | $958.48M-0.6% | $989.24M+9.0% | ||
| $2.93B+25.6% | $2.81B+18.7% | $2.48B+3.2% | $2.29B-1.5% | $2.33B+3.1% | ||
| —— | —— | $615.5M+75.8% | $776.08M+191% | $619.65M+193% | ||
| $22.99M+91.9% | $10.9M-14.0% | $10.7M-33.9% | $11.09M-34.8% | $11.98M-30.3% | ||
| —— | —— | —— | —— | —— | ||
| $412.75M-38.8% | $509.63M-5.9% | $679.27M+73.5% | $840.04M+181% | $674.31M+184% | ||
| $116.85M-22.3% | $133.58M+16.3% | $158.86M+126% | $182.8M+324% | $150.42M+357% | ||
| —— | —— | $520.42M+61.5% | $657.24M+156% | $523.88M+155% | ||
| —— | —— | $2.67+60.8% | $3.38+156% | $2.70+155% | ||
| $436.51M-38.6% | $536.42M-7.6% | $698.22M+55.2% | $859.33M+130% | $710.79M+124% | ||
| 13.5%-10.6pp | 16.7%-3.7pp | 22.6%+6.2pp | 28%+13.6pp | 24.1%+11.3pp | ||
| $362.61M-41.5% | $456.87M-5.6% | $615.5M+75.8% | $776.08M+191% | $619.65M+193% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is BioMarin Pharmaceuticals's revenue?
- BioMarin Pharmaceuticals (BMRN) generated $3.2B in revenue over the trailing twelve months, up 9.9% year over year.
- Is BioMarin Pharmaceuticals profitable?
- BioMarin Pharmaceuticals reported $501.0M in net income over the trailing twelve months, a 16.8% net margin.
- What are BioMarin Pharmaceuticals's profit margins?
- Gross margin is 76.5% and operating margin is 19.9%, with a 16.8% net margin.
- What is BioMarin Pharmaceuticals's earnings per share?
- BioMarin Pharmaceuticals's diluted EPS over the trailing twelve months is $2.56.
- Where does BioMarin Pharmaceuticals's income statement data come from?
- Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
